-
Featured Authors
-
Archives
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
-
Meta
Author Archive: Abigail Hirsch
Abigail is the Manager of Events Communications at BIO. While her time at the organization has been limited, she is quickly learning that staying on top of all the exciting news and happenings within the industry is not easy. Although she has lived in the Washington, DC, area for nearly eight years, she still considers Virginia Beach home, especially with her parents and closest friends still in the area. According to Abigail, there is nothing better than sitting on the beach with a good book and cold drink. In her spare time, she enjoys visiting antique stores, finishing her twin sister Brooke’s sentences and spending time with her two boys, Frank her English bulldog, and JP her soon-to-be husband. Check back often for updates, Abigail’s take on BIO related events, and much more. And please, be kind, this is her first venture in to the blogging world!
Latest Posts
Convention Veterans Putting the “Super” in Super Sessions
Featured in the BIO Buzz Center at last year’s Convention, two of our Super Session participants will once again join us to host a dynamic group of C-level industry thought leaders, sharing their perspectives on the current economic environment and major trends that will impact the future of the global industry. Ernst & Young will present insights from their annual report which looks to measure the industry performance through key metrics such as financial results, Read More >
Tracks & Attendees Put the “International” in the BIO International Convention
As the BIO International Convention celebrates its 20th year, there is no time like the present to reflect on the evolution of the world’s largest biotechnology industry gathering, and what it illustrates in terms of the patterns of global industry achievements. Overall attendance growth over the years – from a 4,000-strong audience in 1998 to an audience topping 16,000 in 2012 – provides a clear indication of how far this industry has come towards developing and Read More >
Onyx CEO One of 25 Most Influential People in Biopharm Today According to FierceBiotech
After a stellar year, as evidenced by inclusion in the second annual FierceBiotech “25 Most Influential People in Bipoharma Today,” N. Anthony (Tony) Coles, MD, Chairman & CEO of Onyx Pharmaceuticals sat down with Steve Usdin, Senior Editor of BioCentury for an early morning Fireside Chat at the 15th Annual BIO CEO & Investor Conference. To read more about Onyx’s stellar year and their company milestones, visit here. The biotech retained complete control in the Read More >
Word on the Street – Biotech Stocks Only Have Room to Go Up
The Opening Lunch Plenary at this year’s BIO CEO & Investor Conference was a lively discussion between portfolio managers and senior buy-side analysts looking to forecast the year ahead in biotech. BIO’s own, Celia Economides, Director, Investor Relations & Programs, reminded us all where we were 15 years ago at the inception of this event. At the 1999 event, there were 18 presenting companies, zero 1X1 meetings scheduled and 271 attendees. As of day one, Read More >
Renewing the Project BioShield Act: What Has It Bought and Wrought?
In the next several months, the U.S. Government will decide whether to continue the funding and authorities associated with Project BioShield, which expanded the U.S. stockpile of medical countermeasures (MCMs) for potential chemical, biological, radiological and nuclear (CBRN) attacks. Congress established Project BioShield in 2004 and provided $5.68B for procurement over 10 years. Two years later, it created the Biomedical Advanced Research and Development Authority (BARDA) to oversee BioShield’s advanced development and procurement efforts. To Read More >
